Vir Biotech partners with WuXi on COVID-19 antibody treatment

27-02-2020

Sarah Morgan

Vir Biotech partners with WuXi on COVID-19 antibody treatment

Karol Ciesluk / Shutterstock.com

Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.


Vir Biotechnology, WuXi Biologics, COVID-19, coronavirus, R&D, biotech, antibodies, collaborations

LSIPR